Home Investing Ozempic maker Novo Nordisk lowers growth outlook for its weight loss drugs as pricing pressures mount

Ozempic maker Novo Nordisk lowers growth outlook for its weight loss drugs as pricing pressures mount

by admin

Novo Nordisk is currently locked in a bidding war with Pfizer for U.S. biotech firm Metsera.

You may also like

Leave a Comment

five × 4 =